Canaccord Genuity Maintains Buy on Connect Biopharma Hldgs, Lowers Price Target to $6

Benzinga Newsdesk www.benzinga.com Negative 74.2%

Neg 74.2% Neu 0% Pos 0%

Canaccord Genuity analyst Edward Nash maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and lowers the price target from $7 to $6.